CIK 0001497253
- Non-accelerated filer
- Smaller reporting company
VivoSim Labs, INC.
Sign in to watch- Ticker
- VIVS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Mar 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 271488943
- Phone
- +1 858-224-1000
- Business address
- 11555 SORRENTO VALLEY ROAD, SUITE 100, SAN DIEGO, CA, 92121
- Former names
- ORGANOVO HOLDINGS, INC., REAL ESTATE RESTORATION & RENTAL, INC.
- Open-market buys, last 90 days
- $2,804
- in 1 filing
- Open-market sales, last 90 days
- $0
- in 0 filings
Net +$2,804. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 60 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-02-16 | Gallant Paul General Manager | Shares withheld for taxes | −7,820 | $1.09 | $8K | 180,579 |
| 2018-02-16 | Bush Jennifer General Counsel & Secretary | Shares withheld for taxes | −10,365 | $1.09 | $11K | 244,815 |
| 2017-11-24 | Murphy Keith Former affiliate last filing | Purchase | +200,500 | $1.49 | $299K | 6,373,673 |
| 2017-11-22 | Murphy Keith Former affiliate last filing | Purchase | +135,000 | $1.50 | $202K | 6,173,173 |
| 2017-11-16 | Presnell Sharon Collins Chief Scientific Officer | Shares withheld for taxes | −5,860 | $1.47 | $9K | 287,213 |
| 2017-11-16 | KUSSMAN CRAIG Chief Financial Officer | Shares withheld for taxes | −11,890 | $1.47 | $17K | 313,748 |
| 2017-11-16 | Gallant Paul General Manager | Shares withheld for taxes | −7,015 | $1.47 | $10K | 188,399 |
| 2017-11-16 | David Eric CSO & EVP Pre-Clinical Dev | Shares withheld for taxes | −5,625 | $1.47 | $8K | 876,609 |
| 2017-11-16 | Bush Jennifer General Counsel & Secretary | Shares withheld for taxes | −8,900 | $1.47 | $13K | 255,180 |
| 2017-08-24 | Maroun Richard E Director | Grant or award · Stock Option (Right to Buy) | +42,500 | 42,500 | ||
| 2017-08-24 | Malloy Kirk Director | Grant or award · Stock Option (Right to Buy) | +42,500 | 42,500 | ||
| 2017-08-24 | KESSEL MARK Director | Grant or award · Stock Option (Right to Buy) | +42,500 | 42,500 | ||
| 2017-08-24 | HOWSON TAMAR D Director | Grant or award · Stock Option (Right to Buy) | +42,500 | 42,500 | ||
| 2017-08-24 | GLOVER JAMES T Director | Grant or award · Stock Option (Right to Buy) | +42,500 | 42,500 | ||
| 2017-08-24 | Baltera Robert Jr. Director | Grant or award · Stock Option (Right to Buy) | +42,500 | 42,500 | ||
| 2017-08-16 | Presnell Sharon Collins Chief Scientific Officer | Shares withheld for taxes | −6,115 | $2.06 | $13K | 293,073 |
| 2017-08-16 | KUSSMAN CRAIG Chief Financial Officer | Shares withheld for taxes | −26,362 | $2.06 | $54K | 325,638 |
| 2017-08-16 | Gallant Paul General Manager | Shares withheld for taxes | −7,324 | $2.06 | $15K | 195,414 |
| 2017-08-16 | David Eric CSO & EVP Pre-Clinical Dev | Shares withheld for taxes | −8,469 | $2.06 | $17K | 882,234 |
| 2017-08-16 | Bush Jennifer General Counsel & Secretary | Shares withheld for taxes | −5,871 | $2.06 | $12K | 264,080 |
Page 8 of 13 · 259 trades